
Health Canada greenlights Neuren Pharmaceuticals' Phase 3 NNZ-2591 trial
Health Canada has approved Neuren Pharmaceuticals' (ASX:NEU) clinical trial application for the Koala Phase 3 clinical trial evaluating NNZ-2591 for the treatment of Phelan-McDermid syndrome in children aged three to 12 years, clearing the way for the inclusion of clinical trial sites in Canada.
The Melbourne-based company said the trial had already received Investigational New Drug approval from the US Food and Drug Administration, with enrolment underway, and confirmed that a second US site in California has now been activated and is enrolling participants.
Neuren CEO Jon Pilcher said the approval marked a further regulatory milestone for the first ever Phase 3 trial in PMS, adding that the company looked forward to working with investigators and the PMS community in Canada while continuing to expand enrolment across both the east and west coasts of the United States.
At the time of reporting, Neuren Pharmaceuticals' share price was $20.04.
More from Australia
Red Metal JV starts 750m Sharon Dam hole
Banks call 4.85% rate peak despite Bullock’s inflation warning
Finbar buys A$7.5m Ascot site for A$166m project
Empire Resources starts 2,000m RC drilling at Yuinmery
Artemis begins 750m drill hole at Sharon Dam
Environmental Group lifts debt facilities to A$12.5m